REG - Cizzle Biotechnology - Result of AGM

Cizzle Biotechnology HoldingsAnnouncement

24/06/2024 12:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240624:nRSX6238Ta&default-theme=true

RNS Number : 6238T  Cizzle Biotechnology Holdings PLC  24 June 2024

24 June 2024

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology" or the "Company")

Result of AGM

Cizzle Biotechnology, the UK-based diagnostics developer, announces that at
the Annual General Meeting ("AGM") of the Company held earlier today, all
resolutions were voted on by a show of hands and were passed.

The proxy votes cast in respect of the resolutions were as follows:

 Resolution                                                                      For                 Against             Votes withheld
                                                                                 Total votes  %      Total votes  %
 1.  To receive the Company's annual report and accounts for the year ended 31   75,934,412   93.27  5,924,896    6.73   2
 December 2023
 2.   To approve the Directors' Remuneration Report                              75,900,186   93.23  5,924,896    6.77   10
 3.   To re-appoint John Michael Treacy as a Director of the Company                          91.35               8.65   2

                                                                                 74,370,196          5,924,896

 4.   To re-appoint Dawn Coverly as a Director of the Company                    75,700,196   92.98  5,924,896    7.02   0
 5.   To re-appoint Nigel Ronald Lee as a Director of the Company                75,734,386   93.03  5,924,896    6.97   2
 6.   To re-appoint PKF Littlejohn LLP as auditor of the Company                 75,734,398   93.03  5,924,896    6.97

                                                                                                                         0

 7.   To authorise the Directors to determine the auditor's remuneration         75,734,396   93.03  5,924,896    6.97

                                                                                                                         2
 8.   Authorises the Directors to allot shares in the Company or to grant        72,596,681   89.17  5,924,896    10.83  0
 rights to subscribe for, or to convert any security into, shares in the
 Company
 9.   Authorise the Directors to allot equity securities disapplying             73,960,822   90.92  6,175,857    9.08   63,555
 pre-emption rights
 10. That General Meetings may be called on not less than 14 days' notice        67,739,369   92.52  6,175,857    7.48   8,195,045

 

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited                                     +44(0) 20 3328 5656
 John Depasquale/George Payne (Corporate Finance)
 Stefano Aquilino/Amrit Nahal (Sales and Corporate Broking)

 

 Novum Securities Limited  +44(0) 20 7399 9400
 Colin Rowbury

 Jon Bellis

 

 IFC Advisory Limited  +44(0) 20 3934 6630
 Tim Metcalfe
 Florence Chandler

 

About Cizzle Biotechnology

Cizzle is developing a blood test for the early detection of lung cancer. The
Company is a spin- out from the University of York, founded in 2006, around
the work of Professor Coverley and colleagues. Its proof-of-concept prototype
test is based on the ability to detect a stable plasma biomarker, a variant of
CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein
involved in DNA replication, and the targeted CIZ1B variant is highly
correlated with early-stage lung cancer. For more information, please
see https://cizzlebiotechnology.com (https://cizzlebiotechnology.com/)

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSEFFFLELSELM